Safety Issues Not Dampening AbbVie Optimism For Humira Successors
Executive Summary
AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.
You may also be interested in...
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.
ACR Roundup: JAK Safety Shown Across Multiple Trials
Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.